Please login to the form below

Not currently logged in
Email:
Password:

anti-cholesterol

This page shows the latest anti-cholesterol news and features for those working in and with pharma, biotech and healthcare.

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

The UK’s health technology assessment body, the National Institute for Health and Care Excellence (NICE), has approved the use of Novartis’ novel anti-cholesterol drug Leqvio (inclisiran) for people with ... The drug is a PCSK9 inhibitor, a novel

Latest news

  • NICE backs use of anti-cholesterol drug Ezetrol NICE backs use of anti-cholesterol drug Ezetrol

    Draft guidance reflects 'greater emphasis on managing CVD risk'. NICE has recommended Merck Sharp &Dohme's cholesterol drug Ezetrol (ezetimibe) in draft guidance. ... In this way Ezetrol can be combined with statins to provide a complementary or

  • FDA approves four new medicines across multiple areas FDA approves four new medicines across multiple areas

    Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals. The FDA has given the green light to four major new treatments for skin cancer, patients with high cholesterol and ... First up, Sanofi and Regeneron's eagerly anticipated injected

  • Sanofi and Regeneron pay $67.5m to speed alirocumab review Sanofi and Regeneron pay $67.5m to speed alirocumab review

    Buy FDA priority review voucher from BioMarin. Sanofi and Regeneron Pharmaceuticals are paying $67.5m for an unusual licence which could enable them to get anti-cholesterol product alirocumab onto the

  • Amgen profits down on rising costs Amgen profits down on rising costs

    Broadway pointed to the start of phase III trials for four new projects in 2012, namely anti-cholesterol antibody AMG-145, romosuzamab for osteoporosis, brodalumab for psoriasis and rilotumamab for gastric

  • Philippines forces drug price cuts

    The mandatory 50 per cent price cuts will cover the anti-hypertensive amlodipine, the antibiotic azithromycin, cholesterol-lowering atorvastatin and two cancer treatments – doxorubicin and cytarabine.

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....